A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids

Cardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent maj...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2017-02, Vol.34 (2), p.300-323
Main Author: Karalis, Dean G.
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular Diseases - prevention & control
Endocrinology
Fatty Acids, Omega-3 - pharmacology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hypertriglyceridemia - complications
Hypertriglyceridemia - diagnosis
Hypertriglyceridemia - drug therapy
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Pancreatitis - etiology
Pancreatitis - prevention & control
Pharmacology/Toxicology
Practice Guidelines as Topic
Review
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent major adverse CV events, statins have emerged as the drug of choice to lower LDL cholesterol and reduce CV risk. However, some statin-treated patients remain at high residual risk of CV events despite achieving low LDL cholesterol levels, especially if their triglyceride (TG) levels are elevated or their high-density lipoprotein (HDL) cholesterol levels low. Evidence from genetic and observational studies has linked elevated TG levels to an increased risk of CV events. Furthermore, very high TG levels are associated with acute pancreatitis. Consequently, several clinical practice guidelines provide recommendations for the management and treatment of high and very high TG levels. This review focuses on the clinical practice guidelines for the management of hypertriglyceridemia and the role of prescription omega-3 fatty acids in preventing pancreatitis and CV disease in individuals with high and very high TG levels.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-016-0462-y